Clinical Trial Update: Impact of Roflumilast on Visceral Adiposity and Metabolic Profile in Chronic Obstructive Pulmonary Disease [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating roflumilast for visceral adiposity and metabolic parameters in chronic obstructive pulmonary disease with metabolic syndrome was termin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease
• Metabolic Syndrome

Drugs mentioned

• Roflumilast (roflumilast)

Snippet

Sponsor: Laval University | Conditions: Chronic Obstructive Pulmonary Disease, Metabolic Syndrome | Phase 2 | Status: TERMINATED